| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EPG5 |
| Uniprot No | Q9HCE0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-464aa |
| 氨基酸序列 | MIVCLLFMMILLAKEVQLVDQTDSPLLSLLGQTSSLSWHLVDIVSYQSVLSYFSSHYPPSIILAKESYAELIMKLLKVSAGLSIPTDSQKHLDAVPKCQAFTHQMVQFLSTLEQNGKITLAVLEQEMSKLLDDIIVFNPPDMDSQTRHMALSSLFMEVLMMMNNATIPTAEFLRGSIRTWIGQKMHGLVVLPLLTAACQSLASVRHMAETTEACITAYFKESPLNQNSGWGPILVSLQVPELTMEEFLQECLTLGSYLTLYVYLLQCLNSEQTLRNEMKVLLILSKWLEQVYPSSVEEEAKLFLWWHQVLQLSLIQTEQNDSVLTESVIRILLLVQSRQNLVAEERLSSGILGAIGFGRKSPLSNRFRVVARSMAAFLSVQVPMEDQIRLRPGSELHLTPKAQQALNALESMASSKQYVEYQDQILQATQFIRHPGHCLQDGKSFLALLVNCLYPEVHYLDHIR |
| 分子量 | 78.8 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人EPG5蛋白的3篇代表性文献的简要列举：
---
1. **文献名称**：EPG5 deficiency leads to premature senescence by disrupting myosin chaperone-mediated autophagy
**作者**：Zhao YG, Zhang H
**摘要**：该研究通过CRISPR/Cas9敲除EPG5基因，发现细胞自噬体与溶酶体融合受阻，导致异常蛋白聚集和细胞早衰。重组EPG5蛋白恢复实验表明其通过调控肌球蛋白介导的膜融合维持自噬通量。
---
2. **文献名称**：Cryo-EM structure of the human EPG5-Rab7 complex reveals a tethering mechanism for autophagosome-lysosome fusion
**作者**：Cheng X et al.
**摘要**：作者利用冷冻电镜解析了重组人EPG5与Rab7蛋白的复合物结构，揭示了EPG5通过N端结构域结合Rab7-GTP，并通过C端螺旋桥接自噬体膜，为自噬体-溶酶体膜融合机制提供了结构基础。
---
3. **文献名称**：Restoration of EPG5 function rescues cardiomyopathy in a Vici syndrome model
**作者**：Byrne S et al.
**摘要**：本研究在EPG5缺陷小鼠模型中，通过腺病毒递送重组人EPG5蛋白，显著改善心肌细胞自噬功能障碍和线粒体异常，验证了EPG5基因疗法对Vici综合征相关心肌病的潜在疗效。
---
这些文献分别从功能机制、结构生物学和疾病治疗角度探讨了重组EPG5蛋白的作用，覆盖了基础研究到应用转化的关键方向。
Recombinant human EPG5 (ectopic P-granules protein 5) is a key autophagy-related protein encoded by the EPG5 gene. It plays a critical role in autophagosome-lysosome fusion, a vital step in autophagy, the cellular degradation pathway that removes damaged organelles and protein aggregates. EPG5 facilitates membrane tethering and fusion by interacting with syntaxin 17 (STX17) and SNAP29 on autophagosomes and lysosomes, respectively. Mutations in EPG5 are associated with Vici syndrome, a rare autosomal recessive disorder characterized by multisystem involvement, including neurodevelopmental defects, immune deficiencies, and cataracts. Structurally, EPG5 contains clathrin-binding domains, suggesting a role in membrane trafficking. Recombinant EPG5 protein is engineered using expression systems (e.g., mammalian, bacterial, or insect cells) for functional studies, enabling researchers to dissect its molecular interactions, autophagic mechanisms, and disease-related dysfunctions. Its production allows in vitro analysis of phosphorylation, ubiquitination, or mutation effects on activity. Additionally, recombinant EPG5 is used in drug screening to identify compounds modulating autophagy, with potential therapeutic applications for Vici syndrome or other autophagy-linked conditions like neurodegeneration and cancer. High-purity recombinant EPG5 aids in antibody development, structural studies (via crystallography or cryo-EM), and cellular rescue experiments to probe genotype-phenotype correlations. Ongoing research focuses on its role in selective autophagy and crosstalk with other degradation pathways.
×
